<DOC>
	<DOCNO>NCT02934828</DOCNO>
	<brief_summary>The investigator research aim explore optimal comprehensive treatment TNBC her2 positive breast cancer compare efficacy neoadjuvant adjuvant treatment improvement RFS .</brief_summary>
	<brief_title>Study Preoperative Chemotherapy Early Triple Negative HER2-positive Operable Breast Cancer</brief_title>
	<detailed_description>Neoadjuvant Chemotherapy ( NCT ) standard treatment patient hope breast-conserving therapy ( BCT ) locally advance inoperable breast cancer large tumor size . beneficial degrade tumor stage , increase rate surgical resection BCT.People pathological complete response ( pCR ) NCT improvement disease-free survival ( DFS ) overall survival ( OS ) , well good prognosis . Currently , breast cancer enter era molecular classification . Different molecular subtype breast cancer show significant difference prognosis ; triple negative breast cancer ( TNBC ) Her2 positive breast cancer clinically relevant term refer specific subtype breast cancer high malignant characteristic , early recurrence metastasis , sensitive primary chemotherapy , proportion 15 % 20 % respectively . A meta analysis show TNBC her2 positive breast cancer high pCR Luminal A/B , increase pCR rate mean improvement survival . The investigator previous study indicate paclitaxel plus carboplatin without trastuzumab improve pCR prolong RFS TNBC her2 positive breast cancer Comparing adjuvant chemotherapy . The investigator research aim explore optimal comprehensive treatment TNBC her2 positive breast cancer compare efficacy neoadjuvant adjuvant treatment improvement RFS .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Invasive breast cancer confirm pathology evaluation core biopsy 2 . Tumors must ER/PgR status negative ( immunohistochemistry（IHC） &lt; 10 % ) lack HER2/neu overexpression amplification measure local hospital pathology laboratory ( IHC +/ fluorescence situ hybridization ( FISH ) IHC &lt; 3+ , FISH &lt; 2.2 ) describe NCCN Guidelines 3 . Female between18 70 year age , Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 4 . Earlystage TNBC HER2 positive breast cancer accord American Joint Committee Cancer ( AJCC ) Staging Manual Clinical Stage IIA IIB , Stage IIIA operable breast cancer 5 . Previously untreated 6 . Adequate hematologic function ( absolute neutrophil count ≥ 1,500 cells/µL ; hemoglobin &gt; 9 g/dL , platelet &gt; 100,000/µL . ) 7 . Adequate hepatic function : total bilirubin ≤ upper limit normal ( ULN ) , serum albumin ≥≥ 3.0 g/dL , alanine aminotransferase aspartate aminotransferase ≤ 1.5 x ULN . 1 . ICH : ER/PgR status positive 2 . HER2 positive breast cancer Patients reduce ejection fraction &lt; 50 % eligible 3 . Patients second malignancy 4 . Patients bilateral breast cancer 5. allergic constitution</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>